COVID-19 Unveils Social Media Might: Is Pharma Listening Hard Enough?
COVID-19 has generated a mind-boggling one billion-plus mentions on social media, unleashing unstructured big data rich in insights. Experts explain why pharma may well want to“listen in” more raptly to such conversations across therapy areas while shaping some aspects of business strategy.
You may also be interested in...
The president of Takeda’s global vaccines business emphasizes the need to build trust and ensure that pharma is transparent about “what we will and will not know” at the time that COVID-19 vaccines are licensed.
Expert outlines how pharma can create resilient and secure supply chains and some benefits of localization.
Biocon Biologics upbeat on Lantus follow-on’s long revenue stream and prospects for interchangeability, while operational challenges resulted in some supply constraints during the fiscal second quarter.